Recent Finacing
Recent Raise
AVROBIO develops ex vivo, lentiviral-based gene therapies using a 3rd-generation platform for stable CD34+ stem cell genomic integration, pursuing single-infusion treatments for Fabry disease, AML, and other rare disorders.
